WT1 Mutation Detection by Sequencing
Ordering Recommendation

WT1 testing is appropriate for detecting mutations in exons 7 and 9 as well as for the presence of SNP rs16754 in cases of cytogenetically normal AML.

Polymerase Chain Reaction/Sequencing
Monday and Wednesday
12-14 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Lavender (EDTA) OR bone marrow (EDTA). 
Specimen Preparation
Transport 5 mL whole blood (Min: 1 mL) OR 3 mL bone marrow (Min: 1 mL). 
Storage/Transport Temperature
Unacceptable Conditions
Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen specimens. Clotted or severely hemolyzed specimens 
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Component Test Code*Component Chart NameLOINC
2005767WT1 Mutation Results21742-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • CN-AML prognostication
  • rs16754
  • WT1 exons 7, 9, SNP rs16754